logo

Clinical Trial Calendar

Share
Company Name Idera Pharmaceuticals, Inc.
Event Name Overall Response Rate data from phase 2 portion of Phase 1/2 trial of intratumoral IMO-2125
Indication PD-1 refractory metastatic melanoma
Outcome Date
Outcome
Result Date Q1 2018
News
http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=2270115
Return to Clinical Trial Calendar